SpliceBio
PrivateLast Round
Series B
Jun 11, 2025
Total Funding Raised
$192.34M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
SpliceBio is a biotechnology company that develops genetic medicines through its proprietary Protein Splicing gene therapy platform, enabling the delivery of larger cargo genes for the treatment of incurable genetic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SpliceBio Comparables
Compare SpliceBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| AAVantgarde Bio | 94% | |
| Scriptr Global, Inc. | 83% | |
| Atsena Therapeutics | 82% |
SpliceBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 11, 2025 | ||||
| Series A | Feb 16, 2022 | ||||
| Grant | Dec 10, 2020 | ||||
| Seed | Sep 15, 2020 |
SpliceBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Asabys Partners | Series B, Series A, Seed |
| UCB Ventures | Series A, Series B |
| Roche Venture Fund | Series B |
| EQT Life Sciences | Series B |
| New Enterprise Associates | Series A, Series B |
| Ysios Capital | Series B, Seed, Series A |
| UCB Ventures | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors grew 74% MoM, reaching 7.3K.
- Dec 1, 2025
Proprietary platform based on Princeton University's Muir Lab technology.
SpliceBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about SpliceBio's valuation, stock price, and market status.
Is SpliceBio a public or private company?
SpliceBio is a private company.
What is the current stock price of SpliceBio?
SpliceBio is a private company, so its shares have no public market price. Caplight tracks SpliceBio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is SpliceBio worth (valuation)?
Valuation information for SpliceBio is not publicly available.
Can I buy SpliceBio stock?
SpliceBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was SpliceBio's last funding round?
SpliceBio's most recent funding round was Series B on June 11, 2025.
Who are the main investors in SpliceBio?
Key investors in SpliceBio include Asabys Partners, UCB Ventures, EQT Life Sciences, Ysios Capital, UCB Ventures.
Will SpliceBio IPO soon?
No public IPO plans have been announced for SpliceBio.
How can I track SpliceBio secondary market activity?
Caplight tracks bids, offers, and trades in SpliceBio's shares on secondary markets.